Skip to main content
SpringerLink
Log in
Book cover

Minimal Residual Disease in Acute Leukemia 1986 pp 58–67Cite as

The application of monoclonal antibodies for the detection and classification of AML

  • Chapter

  • 47 Accesses

Part of the book series: Developments in Oncology ((DION,volume 45))

Abstract

Acute myeloblastic leukemia (AML) is the most common acute leukemia of adults, and even with considerable improvements in the success of remission induction with chemotherapy, most patients will ultimately die with relapsed leukemia. Despite clinical, morphological, and laboratory evidence of patient heterogeneity, identification of prognostically important subgroups has proven difficult. Age greater than 60 years has been an adverse feature in most studies, and some studies have identified other poor prognostic catagories including a history of myelodysplastic syndrome, prior chemotherapy or radiotherapy, leukemic colony growth characteristics in vitro, presence or absence of bleeding or infection, and the extent of cytogenic abnormalities (1–9). The French-American-British (FAB) classification system for AML based on cell morphology (10,11). Some studies have identified prognostically significant groups within the FAB system (12,13), while others have not (4,14).

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Peterson BA, Bloomfield CD: Treatment of acute nonlymphocytic leukemia in elderly patients: A prospective study of intensive chemotherapy. Cancer 40:647, 1977.

    Article  PubMed  CAS  Google Scholar 

  2. Gale RP: Advances in the treatment of acute myelogenous leukemia. New Engl J Med 300:1189, 1979.

    Article  PubMed  CAS  Google Scholar 

  3. Workshop on Prognostic Factors in Human Acute Leukemia. Edited by TM Fliedner, S. Perry. Oxford, Pergamon Press, 1975.

    Google Scholar 

  4. Mertelsmann R, Thaler T, To L, et al. Morphological classification, response to therapy, and survival in 263 adult patients with acute non-lymphoblastic leukemia. Blood 56:773, 1980.

    PubMed  CAS  Google Scholar 

  5. Bernard P, Reiffers J, Lacombe F et al. A stage classification for prognosis in adult acute myelogenous leukaemia based upon patient age, bone marrow karyotype and clinical features. Scand J Haematol 32:429–440, 1984.

    Article  PubMed  CAS  Google Scholar 

  6. McCulloch EA, Curtis JE, Messner HA et al. The contribution of blast cell properties to outcome variation in acute myeloblastic leukemia (AML). Blood 59:601–608, 1982.

    PubMed  CAS  Google Scholar 

  7. Preisler HD, Azarnia N, Raza A et al. Relationship between the percent of marrow cells in S phase and the outcome of remission-induction therapy for acute nonlymphocytic leukaemia. Brit J Haematol 56:399–407, 1984.

    Article  CAS  Google Scholar 

  8. Larson RA, LeBeau MM, Vardiman JW et al. The predictive value of initial cytogenetic studies in 148 adults with acute nonlymphocytic leukemia: a 12-year study (1970–1982). Cancer Genet Cytogenet 10:219–236, 1983.

    Article  PubMed  CAS  Google Scholar 

  9. Greenberg PL. The smoldering myeloid leukemic state: clinical and biologic features. Blood 61:1035–1044, 1983.

    PubMed  CAS  Google Scholar 

  10. Bennet JM, Catovsky D, Daniel MT, Fladrin G, Galton DAG, Gralnick H, Sultan C. Proposals for the classification of the acute luekemias. Br J Haematol 33:451–458, 1976.

    Article  Google Scholar 

  11. Gralnick HR, Galton DAG, Catovsky D, Sultan C, Bennet JM: Classification of acute leukemia. Ann Int Med 87:740–753, 1977.

    Google Scholar 

  12. Bennett JM, Begg C. Eastern Cooperative Group Study of the cytochemistry of adult acute myeloid leukemia by correlation of subtypes with response and survival. Cancer Res 41:4833–4837, 1981.

    PubMed  CAS  Google Scholar 

  13. Sultan C et al. Distribution of 250 cases of acute myeloid leukemia (AML) according to the FAB classification and response to therapy. Br J Haematol 47:545, 1981.

    Article  PubMed  CAS  Google Scholar 

  14. Foon KA et al. Acute myelogenous leukemia: morphologic classification and response to therapy. Leuk Res 3:171, 1979.

    Article  PubMed  CAS  Google Scholar 

  15. Sallen SE, Ritz J, Pesando J, Gelber R, O’Brien C, Hitchcock S, Coral F, Schlossman SF. Cell surface antigens: Prognostic implications in childhood acute lymphoblastic leukemia. Blood 55:395–402, 1980.

    Google Scholar 

  16. Bloomfield CD, Gajl-Peczalska KJ: The clinical relevance of lymphocyte surface markers in leukemia and lyphoma. Curr Top Hematol 3:175–240, 1980.

    PubMed  CAS  Google Scholar 

  17. Chan LC, Pegram SM, Greaves MF: Contribution of the immunophenotype to the classification and differential diagnosis of acute leukemia. Lancet 1:475, 1985.

    Article  PubMed  CAS  Google Scholar 

  18. Ball ED, Fanger MW: Monoclonal antibodies reactive with human myeloid leukemia cells. Clin Exp Immunol 48:655–665, 1982.

    PubMed  CAS  Google Scholar 

  19. Ball ED, Kadushin JM, Schacter B, Fanger MW: Studies on the ability of monoclonal antibodies to selectively mediate complement-dependent cytotoxicity of human myelogenous leukemia blast cells. J Immunol 128:1476–1481, 1982.

    PubMed  CAS  Google Scholar 

  20. Ball ED, Fanger MW. The expression of myeloid-specific antigens on myeloid leukemia cells: correlations with leukemias subclasses and implications for normal myeloid differentiation. Blood 61:456–463, 1983.

    PubMed  CAS  Google Scholar 

  21. Perussia B, Lebman D, Ip SH, Rovera G, Trinchieri G. Terminal differentiation surface antigens of myelomonocytic cells are expressed in human promyelocytic leukemia cells (HL60) treated with chemical inducers. Blood 58:836–843, 1981.

    PubMed  CAS  Google Scholar 

  22. Majdic O, Liszka K, Lutz D, Knapp W. Myeloid differentiation antigen defined by a monoclonal antibody. Blood 58:1127–1133, 1981.

    PubMed  CAS  Google Scholar 

  23. Linker-Israeli M, Billing RJ, Foon KA, Terasaki PI. Monoclonal antibodies reactive with acutre myelogenous leukemia cells. J Immunol 127:2473–2476, 1981.

    PubMed  CAS  Google Scholar 

  24. McKolanis Jr et al. Membrane antigens of human myeloid cells defined by monoclonal antibodies. In: Leucocyte Typing, ed. by Bernard A, Boumsell L, Dausset J, Mistein C, Schlossman SF, Springer-Verlag, Berlin, p.387.

    Google Scholar 

  25. Bernstein ID, Andrews RG, Cohen SF, McMaster BE. Normal and malignant human myelocytic and monocytic calls identified by monoclonal antibodies. J Immunol 128:876–881, 1982.

    PubMed  CAS  Google Scholar 

  26. Zola H, McNamara P, Thomas M, Smart IJ, Bradley J. The preparation and properties of monoclonal antibodies against human granulocyte membrane antigens. Br J Haematol 48:481–490, 1981.

    Article  PubMed  CAS  Google Scholar 

  27. Mannoni P, Janowska-Wieczorek A, Turner AR, McGann L, Ture J-M. Monoclonal antibodies against human granulocytes and myeloid differentiation antigens. Human Immunol 5:309–323, 1982.

    Article  CAS  Google Scholar 

  28. Drexler HG et al. The monoclonal antibody MCS-2 in the routine immunodiagnostic service of leukemia phenotyping. Jpn J Cancer Res (Gann) 76:235, 1985.

    CAS  Google Scholar 

  29. Hanjan SNS, Kearney JF, Cooper MD. A monoclonal antibody (MMA) that identifies a differentiation antigen on human myelomonocytic cells. Clin Immunol Immunopathol 23:172–188, 1982.

    Article  PubMed  CAS  Google Scholar 

  30. Todd RF, Nadler LM, Schlossman SF. Antigens on human monocytes identified by monoclonal antibodies. J Immunol 126:1435, 1981.

    PubMed  Google Scholar 

  31. Todd RF III, Schlossman SF. Analysis of antigenic determinants on human monocytes and macrophages. Blood 59:775–786, 1982.

    PubMed  CAS  Google Scholar 

  32. Civin C, Mirro J, Banquerigo ML. MY1, a new myeloid specific antigen identified by a mouse monoclonal antibody. Blood 57:842–845, 1981.

    PubMed  CAS  Google Scholar 

  33. Griffin JD, Ritz J, Nadler LM, Schlossman SF. Expression of myeloid differentiation antigens on normal and malignant myeloid cells. J Clin Invest 68:932–941, 1981.

    Article  PubMed  CAS  Google Scholar 

  34. Griffin JD, Ritz J, Beveridge RP, Lipton JM, Daley JF, Schlossman SF. Expression of MY7 antigen on myeloid precursor cells. Int J Cell Cloning 1:33–48, 1983.

    Article  PubMed  CAS  Google Scholar 

  35. Griffin JD, Linch DC, Schlossman SF. A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. Leuk Res 8:521–534, 1984.

    Article  PubMed  CAS  Google Scholar 

  36. Civin CI, Vanghan WP, Stass LC, Schwartz JF, Karp JE, Burke PJ. Diagnostic and prognostic utility of cell surface markers in acute non-lymphocytic leukemia (ANLL). Exp Hematol 11 (Supplement 14):152a, 1983.

    Google Scholar 

  37. Civin CI et al. Antigenic analysis of hematopoiesis. III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells. J Immunol 133:157, 1984.

    PubMed  CAS  Google Scholar 

  38. Ball ED, Graziano RF, Fanger MW: A unique antigen expressed on myeloid cells and acute leukemia blast cells defined by a monoclonal antibody. J Immunol 130:00, 1983.

    CAS  Google Scholar 

  39. Beverly PCL, Linch D, Delia D. Isolation of human heamatopoietic progenitor cells using monoclonal antibodies. Nature 287:332–333, 1980.

    Article  Google Scholar 

  40. Linch DC, Allen C, Beverly PCL, Bynoe AG, Scott CS, Hogg N. Monoclonal antibodies differentiating between monocytic and non-monocytic variants of AML. Blood 63:566–573, 1984.

    PubMed  CAS  Google Scholar 

  41. Majdic O et al. M2, a novel myelomonocytic cell surface antigen and its distribution on leukemic cells. Int J Cancer 33:617, 1984.

    Article  PubMed  CAS  Google Scholar 

  42. Knapp W et al. Typing of leukemic cells with monoclonal antibodies. Ann New York Acad Sci 420:251, 1984.

    Article  Google Scholar 

  43. Nadler LM, Ritz J, Griffin JD, Todd RF, Reinherz EL, Schlossman SF. Diagnosis and treatment of human leukemias and lymphomas utilizing monoclonal antibodies. Prog Hematol 12:187–225, 1981.

    PubMed  CAS  Google Scholar 

  44. Van der Reijden HJ, van Rhenen DJ, Lansdorp PM, van ’t Veer MB, Langenhuijsen MMAC, Englefriet CP, von dem Borne AEGK. A comparison of surface marker analysis and FAB classification in acute myeloid leukemia. Blood 61:443–448, 1983.

    PubMed  Google Scholar 

  45. Griffin JD, Mayer RJ, Weinstein HJ, Rosenthal DS, Coral FS, Beveridge RP, Schlossman SF. Surface marker analysis of acute myeloblastic leukemia: Identification of differentiation-associated phenotypes. Blood 62:557–563, 1983.

    PubMed  CAS  Google Scholar 

  46. Moore MAS, Williams N, and Metcalf D. In vitro colony formation by normal and leukemic human hematopoietic cells: Characterization of the colony-forming cells. J Natl Cancer Inst 50:603–623, 1973.

    PubMed  CAS  Google Scholar 

  47. Buick RN, Till JE, and McCulloch EA. Colony assay for proliferative blast cells circulating in myeloblastic leukemia. Lancet 1:862–863.

    Google Scholar 

  48. Minden MD, Till JE, and McCulloch EA. Proliferative state of blast cell progenitors in acute myeloblastic leukemia (AML). Blood 52:592–600, 1978.

    PubMed  CAS  Google Scholar 

  49. Buick RN, Minden MD, and McCulloch EA. Self-renewal in culture of proliferative blast progenitor cells in acute myeloblastic leukemia. Blood 54:95–104, 1979.

    PubMed  CAS  Google Scholar 

  50. Wouters R, Lowenberg B. On the maturation order of AML cells: A distinction on the basis of self-renewal properties and immunologic phenotypes. Blood 63:684–689, 1984.

    PubMed  CAS  Google Scholar 

  51. Griffin JD, Larcom P, and Schlossman SF. Use of surface markers to identify a subset of acute myelomonocytic leukemia cells with progenitor cell properties. Blood 62:1300–1303.

    Google Scholar 

  52. Lange B, Ferrero D, Pessano S, Polumbo A, Faust J, Meo P, and Rovera G. Surface phenotype of clonogenic cells in acute myeloid leukemia defined by monoclonal antibodies. Blood 64:693–700.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dana-Farber Cancer Institute, Boston, MA, 02115, USA

    James D. Griffin M.D.

Authors
  1. James D. Griffin M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The Dr. Daniël den Hoed Cancer Center, P.O. Box 5201, 3008 AE, Rotterdam, The Netherlands

    Anton Hagenbeek MD, PhD  & Bob Löwenberg MD, PhD  & 

  2. Radiobiological Institute TNO, P.O. Box 5815, 2280 HV, Rijswijk, The Netherlands

    Anton Hagenbeek MD, PhD

Rights and permissions

Reprints and permissions

Copyright information

© 1986 Martinus Nijhoff Publishers, Dordrecht

About this chapter

Cite this chapter

Griffin, J.D. (1986). The application of monoclonal antibodies for the detection and classification of AML. In: Hagenbeek, A., Löwenberg, B. (eds) Minimal Residual Disease in Acute Leukemia 1986. Developments in Oncology, vol 45. Springer, Dordrecht. https://doi.org/10.1007/978-94-009-4273-8_6

Download citation

  • DOI: https://doi.org/10.1007/978-94-009-4273-8_6

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-8398-0

  • Online ISBN: 978-94-009-4273-8

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation